Document is current
Any future updates will be listed below
-
Authors
Phadke, Sneha https://orcid.org/0000-0002-9829-1066
Miller, Kathy D.
Shah, Ami
Danciu, Oana C.
Chen, Yi
Yu, Menggang
Burkard, Mark E.
Wisinski, Kari B.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03911973 at ClinicalTrials.govDocuments that mention this clinical trial
Phase I/II trial investigating gedatolisib plus talazoparib in advanced triple negative or BRCA1/2 positive, HER2 negative breast cancers
https://doi.org/10.1007/s10549-025-07747-x
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 4 April 2025
Accepted: 21 May 2025
First Online: 5 June 2025
Declarations
:
: SP serves as a consultant and member of the scientific advisory board for Starling Biosciences, Inc and has research funding from Pfizer, Astra Zeneca, Olema, and Boehringer Ingelheim. KDM serves on IDMCs for Merck, Genentech/Roche, and Celcuity. AS served as a member on a scientific advisory board for Gilead, Lilly, Astrazeneca, Daiichi Sankyo, and Novartis and is on the speakers bureau for Gilead. OCD has research funds from Pfizer and Novartis, Site PI of clinical trials for Pfizer, Novartis, Seagen, Sanofi, Regeneron, Puma, Scientific Advisory Boards for Novartis, Cardinal Health. MEB has research funding from Abbvie, Arcus, Apollomics, Elevation Oncology, Endeavor, Genentech, Puma, Loxo Oncology, Seagen. YC has no COI to report. MY has no COI to report. KBW has grant support from Pfizer and Novartis, Scientific Advisory Boards for Loxo@Lilly, Pfizer, Gilead, Stemline Therapeutics, AstraZeneca. Site PI of clinical trials for Pfizer, Novartis, AstraZeneca, Genentech/Roche, Sanofi, Jazz, Seagen, Relay and Alterome.
: The IRB at each participating institution reviewed and approved the protocol and informed consent documents.
